Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Ofatumumab.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Ofatumumab.
Anthrax immune globulin, human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ofatumumab.
Advertisement
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Ofatumumab.
BCG, Live, Connaught Strain
The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ofatumumab.
BCG, Live, Tice Strain
The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Ofatumumab.
Advertisement
Belimumab
The risk or severity of adverse effects can be increased when Ofatumumab is combined with Belimumab.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Ofatumumab.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Ofatumumab.
Advertisement
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ofatumumab.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Ofatumumab.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Ofatumumab.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Ofatumumab.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Ofatumumab.
Digoxin
Digoxin may decrease the cardiotoxic activities of Ofatumumab.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Ofatumumab.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Ofatumumab.
Hepatitis A Vaccine, Inactivated
The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ofatumumab.
Hepatitis B Surface Antigen Vaccine
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ofatumumab.
Ouabain
Ouabain may decrease the cardiotoxic activities of Ofatumumab.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ofatumumab.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ofatumumab.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Ofatumumab.
Rabies Immune Globulin, Human
The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ofatumumab.
Rabies Virus Vaccine Flury-Lep Strain
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ofatumumab.
ROTAVIRUS VACCINE, LIVE
The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Ofatumumab.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Ofatumumab.
Salmonella enterica subsp. enterica serovar typhi
The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Ofatumumab.
Tetanus Toxoid Vaccine, Inactivated
The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ofatumumab.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Ofatumumab.
Typhoid Vaccine Live Ty21a
The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Ofatumumab.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Ofatumumab.
Varicella Virus Vaccine Live (Oka-Merck) strain
The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Ofatumumab.
Yellow Fever Vaccine
The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Ofatumumab.
Yellow-Fever Virus Vaccine, 17D-204 strain
The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Ofatumumab.
